Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 286

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 286
---
3. A. Operating Results We are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through the co -developmentof Paths DxTest, a novel molecular -basedrapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research. Based on our evaluation of preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors and individual attributes of the Lead Projects themselves. Our goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding our in -housepharmaceutical development center; •Leveraging our management’s expertise, experience and commercial networks; •Obtaining and leveraging government grants to fund project development. We have devoted a substantial portion of the proceeds from our offerings to our Lead Projects. Our Lead Projects are ALS -4, SACT -1and Paths Dx. During the second quarter of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending non -leadR&D projects. This measure is aimed at optimizing the allocation of its resources and focusing its efforts on advancing lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with the Company’s commitment to enhance shareholder value and effectively drive its core objectives forward in the competitive landscape. On March 1, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Company, and YOOV Group Holding Limited, a BVI business company organized under the laws of British Virgin Islands (“YOOV”) to effect a merger